{"id":75205,"date":"2026-08-18T12:11:36","date_gmt":"2026-08-18T04:11:36","guid":{"rendered":"https:\/\/flcube.com\/?p=75205"},"modified":"2026-08-18T12:11:37","modified_gmt":"2026-08-18T04:11:37","slug":"canbridge-pharmaceuticals-livmarli-granted-nhia-reimbursement-approval-in-taiwan-ibat-inhibitor-coverage-for-algs-and-pfic-takes-effect-september-1","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75205","title":{"rendered":"CANbridge Pharmaceuticals&#8217; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CANbridge Pharmaceuticals Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1228:HKG\">HKG: 1228<\/a>) announced that its rare disease drug <strong>Livmarli (Maralixibat Chloride Oral Solution)<\/strong> has been granted <strong>reimbursement approval<\/strong> by Taiwan&#8217;s <strong>National Health Insurance Administration (NHIA)<\/strong>, with coverage set to take effect on <strong>September 1, 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-reimbursement-milestone\" class=\"wp-block-heading\">Reimbursement Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Health Insurance Administration (NHIA), Taiwan<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Reimbursement approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Livmarli (Maralixibat Chloride Oral Solution)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Alagille syndrome (ALGS); progressive familial intrahepatic cholestasis (PFIC)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>18 Aug 2026<\/td><\/tr><tr><td><strong>Coverage Effective Date<\/strong><\/td><td>1 Sep 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Maralixibat chloride, oral solution.<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Minimally absorbed <strong>ileal bile acid transporter (IBAT) inhibitor<\/strong> that blocks the enterohepatic circulation of bile acids.<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Reduces bile acid levels in the liver and serum, decreases resultant liver injury, and alleviates <strong>cholestatic pruritus<\/strong> (extreme itching).<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Treatment of <strong>Alagille syndrome (ALGS)<\/strong> and <strong>progressive familial intrahepatic cholestasis (PFIC)<\/strong>.<\/li>\n\n\n\n<li><strong>Regulatory Footprint:<\/strong> Approved in <strong>China (Mainland, Hong Kong and Taiwan)<\/strong>, the <strong>United States<\/strong> and the <strong>European Union<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Access:<\/strong> NHIA reimbursement removes a key affordability barrier for ALGS and PFIC patients in Taiwan, where both conditions are ultra\u2011rare and treatment options remain limited.<\/li>\n\n\n\n<li><strong>Commercial Trajectory:<\/strong> Coverage effective September 1 positions <strong>Livmarli<\/strong> for near\u2011term uptake within Taiwan&#8217;s single\u2011payer system, adding a reimbursed indication to CANbridge&#8217;s rare disease portfolio.<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> Prior approvals across China, the U.S. and the EU reinforce the clinical and regulatory foundation supporting Livmarli&#8217;s expansion in additional markets.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> For <strong>CANbridge Pharmaceuticals<\/strong> (HKG: 1228), the milestone strengthens its rare disease commercialization platform and broadens the product&#8217;s lifecycle value in Greater China.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding reimbursement implementation and commercial expectations for Livmarli. Actual results may differ due to risks including policy changes, market adoption and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081800014_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026081800014_c.\"><\/object><a id=\"wp-block-file--media-5030f846-4b85-489a-8ccf-d990d27cf875\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081800014_c.pdf\">2026081800014_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081800014_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5030f846-4b85-489a-8ccf-d990d27cf875\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[142,883,24],"class_list":["post-75205","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-canbridge-pharmaceuticals","tag-hkg-1228","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CANbridge Pharmaceuticals&#039; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan&#039;s National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75205\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CANbridge Pharmaceuticals&#039; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1\" \/>\n<meta property=\"og:description\" content=\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan&#039;s National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75205\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-18T04:11:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-18T04:11:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CANbridge Pharmaceuticals&#8217; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1\",\"datePublished\":\"2026-08-18T04:11:36+00:00\",\"dateModified\":\"2026-08-18T04:11:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CANbridge Pharmaceuticals\",\"HKG: 1228\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75205#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75205\",\"name\":\"CANbridge Pharmaceuticals' Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-18T04:11:36+00:00\",\"dateModified\":\"2026-08-18T04:11:37+00:00\",\"description\":\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan's National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75205\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75205#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CANbridge Pharmaceuticals&#8217; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CANbridge Pharmaceuticals' Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1 - Insight, China&#039;s Pharmaceutical Industry","description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan's National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75205","og_locale":"en_US","og_type":"article","og_title":"CANbridge Pharmaceuticals' Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1","og_description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan's National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.","og_url":"https:\/\/flcube.com\/?p=75205","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-18T04:11:36+00:00","article_modified_time":"2026-08-18T04:11:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75205#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75205"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CANbridge Pharmaceuticals&#8217; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1","datePublished":"2026-08-18T04:11:36+00:00","dateModified":"2026-08-18T04:11:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75205"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CANbridge Pharmaceuticals","HKG: 1228","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75205#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75205","url":"https:\/\/flcube.com\/?p=75205","name":"CANbridge Pharmaceuticals' Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-18T04:11:36+00:00","dateModified":"2026-08-18T04:11:37+00:00","description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that its rare disease drug Livmarli (Maralixibat Chloride Oral Solution) has been granted reimbursement approval by Taiwan's National Health Insurance Administration (NHIA), with coverage set to take effect on September 1, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75205#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75205"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75205#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CANbridge Pharmaceuticals&#8217; Livmarli Granted NHIA Reimbursement Approval in Taiwan \u2013 IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75205"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75205\/revisions"}],"predecessor-version":[{"id":75208,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75205\/revisions\/75208"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}